1 active not recruiting, 1 completed, 1 unknown. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow ibudilast: new trials by email Literature Review of ibudilast trials Research Report on ibudilast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Ibudilast, Pentoxifylline, Placebo - Long COVID, Post COVID Condition | Phase 2 / Phase 3 | Completed | University Health Network, Toronto | 460 | 2023-05-31 | 2026-02-23 |
| Regeneration in Cervical Degenerative Myelopathy Ibudilast, Cervical decompressive surgery, Matching placebo - Myelopathy, Spinal Cord Diseases | Phase 3 | Unknown | Cambridge University Hospitals NHS Foundation Trust | 400 | 2021-12-22 | 2022-01-13 |
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS MN-166, placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Active not recruiting | MediciNova | 234 | 2020-05-28 | 2026-03-06 |
Amyotrophic Lateral Sclerosis (1) · Post-Acute COVID-19 Syndrome (1) · Spinal Cord Diseases (1)
Cambridge University Hospitals NHS Foundation Trust (1) · MediciNova (1) · University Health Network, Toronto (1)
Canada (2) · United Kingdom (1) · United States (1)
Angela M Cheung, MD,PhD (1) · Benjamin Davies, MD (1) · George Tomlinson, PhD (1) · Peter Juni, MD, PhD (1)
2017 (1)